ArticleOxford medical case reports2023
Successful treatment of Hidradenitis Suppurativa with tofacitinib: two cases and a review of the literature.
Article in Oxford medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH) syndrome treated with upadacitinib.JAAD case reports · 2026Article
- Real-World Experience with Janus Kinase Inhibitors in Severe Refractory Hidradenitis Suppurativa: A Retrospective Case Series.Clinical, cosmetic and investigational dermatology · 2026Article
- Unravelling the Link Between Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Literature Review.Biomedicines · 2025Review
- Janus Kinase Inhibitors as A Breakthrough Treatment for Refractory Dissecting Cellulitis of the Scalp.European journal of case reports in internal medicine · 2025Article
- Hidradenitis suppurativa: a new therapeutic approach for an old disease.Postepy dermatologii i alergologii · 2024Review
- Tofacitinib in Overlapping Autoimmune and Autoinflammatory Disorders: A Case Report of a Dual Graham-Little-Piccardi-Lasseur Syndrome and Hidradenitis Suppurativa.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis Suppurativa (HS) is a major public health challenge affecting people globally, which is painful and the hard lumps under the skin are prone to infection. We aimed to investigate whether tofacitinib can help people with HS in a safe and effective way. In this study, we report two cases diagnosed with HS. Tofacitinib was used as a part of the treatment plan. The first patient received 5 mg of tofacitinib twice daily, 36 weeks, and the second one for 24 weeks. Clinical outcomes are described. The efficacy of tofacitinib in HS was confirmed in our study. The clinical characteristics of the patients improved after receiving tofacitinib. Lesions discharge significantly reduced, particularly in the axillary area. Tofacitinib may be useful as an adjuvant therapy when used in combination with other treatments. Further research in this area is required to improve our understanding of treatment with tofacitinib at HS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.